Pathogenesis and management of heparin-induced thrombocytopenia and thrombosis
- 4 February 2020
- journal article
- review article
- Published by Elsevier BV in Clinica Chimica Acta; International Journal of Clinical Chemistry
- Vol. 504, 73-80
- https://doi.org/10.1016/j.cca.2020.02.002
Abstract
No abstract availableKeywords
Funding Information
- Medical Science Innovation Project for Youth of Sichuan Province (Q14031)
This publication has 129 references indexed in Scilit:
- Ultra-low-molecular-weight heparins: Precise structural features impacting specific anticoagulant activitiesThrombosis and Haemostasis, 2013
- Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy – A European PerspectiveThrombosis Research, 2012
- Vorapaxar in the Secondary Prevention of Atherothrombotic EventsThe New England Journal of Medicine, 2012
- Treatment and Prevention of Heparin-Induced Thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- Chemoenzymatic Synthesis of Homogeneous Ultralow Molecular Weight HeparinsScience, 2011
- Heparin promotes platelet responsiveness by potentiating αIIbβ3-mediated outside-in signalingBlood, 2011
- Antiplatelet therapy: thrombin receptor antagonistsBritish Journal of Clinical Pharmacology, 2010
- Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopeniaBlood, 2010
- Immune complexes formed following the binding of anti–platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesionBlood, 2008
- Immune Endothelial-Cell Injury in Heparin-Associated ThrombocytopeniaThe New England Journal of Medicine, 1987